MemberJune 1, 2021 at 1:20 pm
<div>A discussion about diagnosing symptoms, and preventing, treating and curing inflammatory reactions in blood vessels and lung tissues as a result of a spike protein infection, also known as an “allergen”.</div><div>
The simple question and answer:
What over-the-counter molecules and compounds can provide relief for inflammation, leading to the immune system preventing further infection? Answer: Anti-inflammatory and anti-viral molecules that work synergistically with the human immune system.
On 12 March 2020, the outbreak of coronavirus disease 2019 (COVID-19)
was declared a pandemic by the World Health Organization. As of 4 August
2020, more than 18 million confirmed infections had been reported
globally. Most patients have mild symptoms, but some patients develop
respiratory failure which is the leading cause of death among COVID-19
patients. Endothelial cells with high levels of angiotensin-converting
enzyme 2 expression are major participants and regulators of
inflammatory reactions and coagulation. Accumulating evidence suggests
that endothelial activation and dysfunction participate in COVID-19
pathogenesis by altering the integrity of vessel barrier, promoting
pro-coagulative state, inducing endothelial inflammation, and even
mediating leukocyte infiltration.
<img loading=”lazy” alt=”An external file that holds a picture, illustration, etc.
Object name is imm0140-0281-f1.jpg” title=”An external file that holds a picture, illustration, etc.
Object name is imm0140-0281-f1.jpg” src=”https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800433/bin/imm0140-0281-f1.jpg”>
Overview of endothelial activation and dysfunction in the pathogenesis
of COVID-19. In the initial stage of severe COVID-19 patients,
SARS-CoV-2 infection causes acute lung injury, and then excessive
cytokines are released from immune cells, bronchial epithelial cells,
and alveolar cells. SARS-CoV-2 infection and various cytokines are
predicted to cause endothelial activation and dysfunction by multiple
pathways, leading to vascular inflammation and permeability. Then more
immune cells enter or migrate into alveoli and enhance lung
acetyl cysteine (NAC)
With regard to its anti-inflammatory action, in contrast, the effects of NAC differ in vivo and in vitro and are highly dose-dependent. In the in vitro settings anti-inflammatory effects are seen at high but not at low concentrations. On the other hand, some long-term effectiveness is reported in several in vivo studies even at low dosages. Increasing the dose seems to improve NAC bioavailability and may also consolidate some of its effects. In this way, the effects that are observed in the clinical and in vivo studies do not always reflect the success of the in vitro experiments. Furthermore, the results obtained with healthy volunteers do not always provide incontrovertible proof of its usefulness in COPD especially when number of exacerbations and changes in lung function are chosen as the primary outcomes. Despite these considerations and in view of the present lack of effective therapies to inhibit disease progression in COPD, NAC and its derivatives, because of their multiple molecular modes of action, remain promising medication once doses and route of administration are optimized.
The results of present study provide further evidence for the
anti-inflammatory effect of fluvoxamine. This effect appears to be
mediated by down regulation of inflammatory genes.
Fluvoxamine may prevent serious illness in COVID-19 patients, study suggests
Antidepressant drug repurposed for patients with coronavirus infection
We regard ivermectin as a core medication in the prevention and treatment of COVID-19. For comprehensive information on ivermectin please refer to our Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19 and the included references.
These pages contain the scientific rationale that justifies the use of ivermectin in COVID-19.
For PATIENTS AND RELATIVES, please review our HELP PAGES. There you can find information on how to find physicians that prescribe ivermectin as well as information you can share with your primary care physician in the event they have not yet been made aware of the current evidence in support of ivermectin’s efficacy in COVID-19 prevention and treatment.
Background Recent research has indicated that vitamin D may have immune
supporting properties through modulation of both the adaptive and innate
immune system through cytokines and regulation of cell signalling
pathways. We hypothesize that vitamin D status may influence the
severity of responses to Covid-19 and that the prevalence of vitamin D
deficiency in Europe will be closely aligned to Covid-19 mortality.
Kara M, Ekiz T, Ricci V, Kara Ö, Chang KV, Özçakar L. Br J Nutr. 2020 Oct 14;124(7):736-741. doi: 10.1017/S0007114520001749. Epub 2020 May 12. PMID: 32393401 Free PMC article.
Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Nutrients. 2020 Apr 2;12(4):988. doi: 10.3390/nu12040988. PMID: 32252338 Free PMC article. Review.
Xu Y, Baylink DJ, Chen CS, Reeves ME, Xiao J, Lacy C, Lau E, Cao H. J Transl Med. 2020 Aug 26;18(1):322. doi: 10.1186/s12967-020-02488-5. PMID: 32847594 Free PMC article. Review.
Ilie PC, Stefanescu S, Smith L. Aging Clin Exp Res. 2020 Jul;32(7):1195-1198. doi: 10.1007/s40520-020-01570-8. Epub 2020 May 6. PMID: 32377965 Free PMC article.
Whittemore PB. Am J Infect Control. 2020 Sep;48(9):1042-1044. doi: 10.1016/j.ajic.2020.06.193. Epub 2020 Jun 26. PMID: 32599103 Free PMC article.
Cited by 46 articles
Bui L, Zhu Z, Hawkins S, Cortez-Resendiz A, Bellon A. SAGE Open Med. 2021 May 18;9:20503121211014073. doi: 10.1177/20503121211014073. eCollection 2021. PMID: 34046177 Free PMC article. Review.
Davoudi A, Najafi N, Aarabi M, Tayebi A, Nikaeen R, Izadyar H, Salar Z, Delavarian L, Vaseghi N, Daftarian Z, Ahangarkani F. BMC Infect Dis. 2021 May 18;21(1):450. doi: 10.1186/s12879-021-06168-7. PMID: 34006228 Free PMC article.
Abraham EH, Guidotti G, Rapaport E, Bower D, Brown J, Griffin RJ, Donnelly A, Waitzkin ED, Qamar K, Thompson MA, Ethirajan S, Robinson K. Purinergic Signal. 2021 May 10:1-12. doi: 10.1007/s11302-021-09771-0. Online ahead of print. PMID: 33970408 Free PMC article.
Heim M, Lahmer T, Rasch S, Kriescher S, Berg-Johnson W, Fuest K, Kapfer B, Schneider G, Spinner CD, Geisler F, Wießner JR, Rothe K, Feihl S, Ranft A. Multidiscip Respir Med. 2021 Apr 2;16(1):744. doi: 10.4081/mrm.2021.744. eCollection 2021 Jan 15. PMID: 33907624 Free PMC article.
Derbyshire EJ, Calder PC. Front Nutr. 2021 Mar 25;8:652469. doi: 10.3389/fnut.2021.652469. eCollection 2021. PMID: 33842525 Free PMC article. Review.
Log in to reply.